Wall Street brokerages expect Genocea Biosciences Inc (NASDAQ:GNCA) to post ($0.14) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Genocea Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.10). Genocea Biosciences posted earnings per share of ($0.48) in the same quarter last year, which would indicate a positive year over year growth rate of 70.8%. The business is expected to issue its next earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.42). For the next financial year, analysts forecast that the business will report earnings of ($0.61) per share, with EPS estimates ranging from ($0.86) to ($0.45). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.03.
A number of brokerages recently issued reports on GNCA. Cantor Fitzgerald set a $5.00 price objective on Genocea Biosciences and gave the company a “buy” rating in a research note on Sunday, March 11th. HC Wainwright began coverage on Genocea Biosciences in a research note on Thursday, March 8th. They issued a “buy” rating and a $5.00 price objective on the stock. Robert W. Baird began coverage on Genocea Biosciences in a research note on Monday, February 12th. They issued an “outperform” rating and a $3.00 price objective on the stock. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Tuesday, February 6th. Finally, Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Genocea Biosciences currently has a consensus rating of “Buy” and an average price target of $4.41.
Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in shares of Genocea Biosciences during the fourth quarter valued at about $145,000. New York State Common Retirement Fund bought a new stake in shares of Genocea Biosciences during the second quarter valued at about $159,000. California State Teachers Retirement System bought a new stake in shares of Genocea Biosciences during the second quarter valued at about $265,000. Northern Trust Corp increased its position in shares of Genocea Biosciences by 642.9% during the second quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock valued at $1,601,000 after buying an additional 265,328 shares during the period. Finally, State Street Corp increased its position in shares of Genocea Biosciences by 1,595.2% during the second quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock valued at $1,912,000 after buying an additional 344,572 shares during the period. Hedge funds and other institutional investors own 10.29% of the company’s stock.
Genocea Biosciences stock traded down $0.08 during midday trading on Monday, reaching $0.97. The stock had a trading volume of 1,441,883 shares, compared to its average volume of 1,235,297. Genocea Biosciences has a 12 month low of $0.79 and a 12 month high of $7.29. The stock has a market capitalization of $86.21, a P/E ratio of -0.49 and a beta of 1.20. The company has a debt-to-equity ratio of -1.26, a quick ratio of 0.83 and a current ratio of 0.83.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.